Valuation
- Market cap
- 2,000
- Revenue TTM
- $80,000
- Net income TTM
- $-1,730,000
- P/E (trailing)
- 0.00
- P/E (forward)
- —
- Profit margin
- -2,162.50%
- Debt to equity
- 0.00
Trading
- Volume
- 100
- Avg volume
- 1,238
- Day's range
- $0.17 – $0.17
- Shares out
- 1,440,000
- Stochastic %K
- 100%
- Beta
- 170.54
- Analysts
- —
- Price target
- $1.50
Company profile
RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, develops pharmaceuticals from Thymosin beta 4 (Tß4) for tissue protection, repair, and regeneration. The company is developing RGN-259, a sterile and preservative-free eye drop that has completed Phase 3 clinical trial for the treatment of dry eye syndrome and neurotrophic keratitis. It has strategic partnerships with Lee's Pharmaceutical Group for the d...
Show more
RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, develops pharmaceuticals from Thymosin beta 4 (Tß4) for tissue protection, repair, and regeneration. The company is developing RGN-259, a sterile and preservative-free eye drop that has completed Phase 3 clinical trial for the treatment of dry eye syndrome and neurotrophic keratitis. It has strategic partnerships with Lee's Pharmaceutical Group for the development and marketing of Tß4-related products; and HLB Therapeutics for the development and marketing of RGN-259, and RGN-137 for dermal wound healing. The company was formerly known as Alpha 1 Biomedicals, Inc. and changed its name to RegeneRx Biopharmaceuticals, Inc. in December 2000. RegeneRx Biopharmaceuticals, Inc. was incorporated in 1982 and is based in Rockville, Maryland.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 301 208 9191
- Website
- https://www.regenerx.com
- Address
- 15245 Shady Grove Road, Suite 470, Rockville, United States
Latest news
No headlines yet.
